Alembic Of India Plans Focus Switch From Local Market To Europe, U.S.
This article was originally published in PharmAsia News
Executive Summary
India's Alembic Pharma plans to shift from producing active pharmaceutical ingredients for the local market to focus on Europe and the United States, which it believes offer greater profitability.
You may also be interested in...
Pfizer’s Hospira Faces 15-Year Wait On US Adrenalin Generic
Hospira’s efforts to circumvent two US patents shielding Par’s Adrenalin (epinephrine) have again ended in failure, following a ruling by the US Court of Appeals for the Federal Circuit.
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
Merz Consumer Care Optimistic About Future As German Lockdown Continues
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
Need a specific report? 1000+ reports available
Buy Reports